Fig. 1 · Structure

Documents & Downloads

LY-2584702

Cat. No. A14202 CAS 1082949-67-4

p70S6K inhibitor

LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.

In Stock

Publications for LY-2584702

1 publication citing this product

  1. Kai-Ching Hsiao, .et al. , Cell Commun Signal, 2023, Jul 10;21(1):172 PMID: 37430297

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

LY-2584702 has been used to probe S6K-dependent cellular signaling. In B56γ3-depleted SW480 colorectal cancer cells, 5 μM LY-2584702 reduced S6 phosphorylation while restoring IGF-1-stimulated AKT phosphorylation. p70S6K Thr389 phosphorylation was not reduced, illustrating why downstream substrate phosphorylation and upstream feedback should be evaluated separately. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
p70S6K 4 nM

LY-2584702 Research Summary

This section summarizes 2 in vitro studies of LY-2584702 from 2 published references. In vitro models include WT and heterozygous PPP2R5D E198K or E420K HEK293 cells.

LY-2584702 In Vitro Studies

In WT and heterozygous PPP2R5D E198K/E420K HEK293 cells, LY2584702 (20 nM, 3 h) reduced RPS6 Ser240/244 phosphorylation and increased p70S6K Thr389 phosphorylation. AKT Ser473 phosphorylation also increased in WT and E198K cells. These model-specific responses support measuring pathway output and feedback together; the experiment did not establish therapeutic benefit. The paper did not specify the tested salt form. [2]

S6K inhibition restores growth-factor-stimulated AKT signaling in B56γ3-depleted SW480 cells

Cell-based study · SW480 colorectal cancer cells: shLuc control versus B56γ3 knockdown (shB56γ3) [1]

At 5 μM, LY-2584702 reduced downstream S6 phosphorylation and restored IGF-1-stimulated AKT phosphorylation in B56γ3-depleted cells. p70S6K Thr389 phosphorylation was not reduced. This supports a feedback response in this defined cellular context, rather than uniform suppression of upstream AKT.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
S6 phosphorylation at Ser240/244qualitative immunoblot response Reduced with LY-2584702 versus B56γ3-knockdown vehicle condition; no numerical effect size extracted.[1]
AKT phosphorylation at Thr308 and Ser473qualitative immunoblot response Restored by LY-2584702 in growth-factor-stimulated B56γ3-depleted cells compared with DMSO-treated knockdown cells.[1]
p70S6K phosphorylation at Thr389qualitative immunoblot response Not reduced by LY-2584702 in this experiment.[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM LY-2584702; IGF-1 stimulation at 50 ng/ml
Exposure duration
Pretreatment followed by 60 min IGF-1 stimulation with LY-2584702 present; drug pretreatment interval not specified in Fig. 3J.
Method
Cellular treatment followed by SDS-PAGE and Western blotting.
Vehicle
DMSO control; vehicle concentration not specified for Fig. 3J.
Co-treatment
IGF-1 is the signaling stimulus; no second pharmacological inhibitor in adopted panel J.
Reported limits
Pretreatment interval, drug lot, catalog number, salt form and DMSO fraction are not specified for the adopted experiment.
Methods and source locations

Compound reported in the paper: LY-2584702; Compound label in the paper: LY-2584702 (Adooq Bioscience), as named in Fig. 3J

Reported cellular behavior of LY-2584702; not a certificate of free-base form, purity or current-lot performance.

Fig. 3J, caption and image; Results Sec17 LY-2584702 rescue paragraph; Methods Sec6 and Sec14

S6 phosphorylation at Ser240/244: SDS-PAGE/Western blot; total S6 and β-actin controls visible. — Fig. 3J, caption and image; Results Sec17 LY-2584702 rescue paragraph; Methods Sec6 and Sec14

AKT phosphorylation at Thr308 and Ser473: Western blot, total AKT control and relative phospho-AKT quantification; caption reports n = 3 independent experiments for quantification. — Fig. 3J, caption and image; Results Sec17 LY-2584702 rescue paragraph; Methods Sec6 and Sec14

p70S6K phosphorylation at Thr389: Western blot with total p70S6K control; pathway output assessed separately by phospho-S6. — Fig. 3J, caption and image; Results Sec17 LY-2584702 rescue paragraph; Methods Sec6 and Sec14

RPS6 suppression with increased p70S6K phosphorylation in PPP2R5D-variant HEK293 cells

Cell-based study · WT and heterozygous PPP2R5D E198K or E420K HEK293 cells [2]

LY2584702 at 20 nM for 3 h reduced RPS6 Ser240/244 phosphorylation while increasing p70S6K Thr389 phosphorylation in WT and variant cells. Supporting blots also showed increased AKT Ser473 phosphorylation in WT and E198K cells. These are cellular phospho-signaling results, not enzyme IC50 or clinical efficacy measurements.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RPS6 Ser240/244 phosphorylation normalized to total RPS6qualitative immunoblot response Reduced after LY2584702 in WT, E420K and E198K cells; within-genotype comparisons marked *p < 0.05.[2]
p70S6K Thr389 phosphorylation normalized to total p70S6Kqualitative immunoblot response Increased after LY2584702 in WT, E420K and E198K cells; within-genotype comparisons marked *p < 0.05.[2]
AKT Ser473 phosphorylationqualitative immunoblot response Reported increased in WT and E198K cells after treatment; no corresponding increase claimed for E420K.[2]

Literature-Reported Treatment Conditions

Treatment concentration
20 nM
Exposure duration
3 h
Method
LY2584702 treatment followed by immunoblot analysis.
Co-treatment
LY2584702 alone in adopted Fig. 7D–F; rapamycin is a separate comparison experiment, not a combination.
Reported limits
Drug supplier, catalog/lot, salt form and vehicle composition are not specified in the inspected original experiment text. Figure shows matched untreated (Tx−) conditions; vehicle matching cannot be established.
Methods and source locations

Compound reported in the paper: LY2584702; Compound label in the paper: LY2584702, as reported by Smolen et al.

Compound-name-level cellular observation only; no transfer of formulation, dose equivalence, or Adooq lot validation.

Fig. 7D–F and caption; Results sec1.8; Methods sec3.4/sec3.7; Supporting information Fig. S11

RPS6 Ser240/244 phosphorylation normalized to total RPS6: Immunoblot/densitometry; N = 3 independent cell experiments, mean ± SD; unpaired t test. — Fig. 7D–F and caption; Results sec1.8; Methods sec3.4/sec3.7; Supporting information Fig. S11

p70S6K Thr389 phosphorylation normalized to total p70S6K: Fig. 7D/E immunoblot and quantification; N = 3 independent cell experiments, mean ± SD; unpaired t test. — Fig. 7D–F and caption; Results sec1.8; Methods sec3.4/sec3.7; Supporting information Fig. S11

AKT Ser473 phosphorylation: Supporting Fig. S11 triplicate immunoblots with pan-AKT controls; one replicate also appears in Fig. 7D. — Fig. 7D–F and caption; Results sec1.8; Methods sec3.4/sec3.7; Supporting information Fig. S11

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1082949-67-4
Applications p70S6K inhibitor
Formula C21H19F4N7
Molecular Weight 445.42
Synonyms LYS6K2
SMILES
CN(C(C1CCN(C2=NC=NC3=NNC=C32)CC1)=N4)C=C4C5=CC(C(F)(F)F)=C(F)C=C5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 1 mg/mL (2.24 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

LY-2584702 Research References

  1. [1] Kai-Ching Hsiao, Siou-Ying Ruan, Shih-Min Chen, et al. The B56γ3-containing protein phosphatase 2A attenuates p70S6K-mediated negative feedback loop to enhance AKT-facilitated epithelial-mesenchymal transition in colorectal cancer. Cell communication and signaling : CCS (2023). PMID: 37430297 DOI: 10.1186/s12964-023-01182-5 Source material
  2. [2] Kali A Smolen, Cinta M Papke, Mark R Swingle, et al. Quantitative proteomics and phosphoproteomics of PP2A-PPP2R5D variants reveal deregulation of RPS6 phosphorylation via converging signaling cascades. The Journal of biological chemistry (2023). PMID: 37572851 DOI: 10.1016/j.jbc.2023.105154 Source material

Publications

1 publication citing this product

  1. Kai-Ching Hsiao, .et al. , Cell Commun Signal, 2023, Jul 10;21(1):172 PMID: 37430297

Added to your cart

View Cart Checkout
Loading...